Influence of PTGS1 gene polymorphisms on efficiency and safety of post-operative Ketorolac treatment of uncomplicated acute calculus cholecystitis

Objective: The study aimed to evaluate the possible association of PTGS1 gene polymorphisms (rs10306135, rs12353214) with the clinical effi cacy and safety of ketorolac in relation to postoperative pain.

Materials and methods: The study included 107 patients after video laparoscopic cholecystectomy, who received ketorolac 30 mg as postoperative pain relief 2.0 x 3 times a day. All patients were genotyped for PTGS1 (rs10306135, rs12353214). The pain syndrome was assessed using the Visual Analog scale (VAS), the McGill pain questionnaire. The profi le of adverse reactions was assessed by the dynamics of red blood counts, as a possible trigger for the development of gastrointestinal bleeding according to the method of global assessment of triggers (GTT).

Results: According to the VAS and the McGill pain questionnaire, there were no statistically signifi cant diff erences in the intensity of pain between the two groups. There were also no statistically signifi cant diff erences in the dynamics of red blood counts.

Conclusion: We did not fi nd an association between the carriage of the PTGS1 genotype (rs10306135, rs12353214) and the effectiveness of postoperative anesthesia with ketorolac, and we did not fi nd an association with the risk of developing adverse reactions after ketorolac anesthesia.

1. Singh G., Triadafi lopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl. 1999;56:18–24.. PMID: 10225536

2. Coxib and traditional NSAID Trialists’ (CNT) Collaboration, Bhala N., Emberson J., et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inf lammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769–779. doi: 10.1016/S0140–6736(13)60900–9

3. Nissen S. E., Yeomans N. D., Solomon D. H., et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016;375(26):2519–2529. doi: 10.1056/NEJMoa1611593

4. Bjarnason I., Scarpignato C., Takeuchi K., Rainsford K. D. Determinants of the short-term gastric damage caused by NSAIDs in man. Aliment Pharmacol Th er. 2007;26(1):95–106. doi: 10.1111/j.1365–2036.2007.03348.x

5. Geis G. S., Stead H., Wallemark C. B., Nicholson P. A. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesions. J Rheumatol Suppl. 1991;28:11–14. PMID: 1903808

6. Bjarnason I., Hayllar J., MacPherson A.J., Russell A. S. Side eff ects of nonsteroidal anti-infl ammatory drugs on the small and large intestine in humans. Gastroenterology. 1993;104(6):1832–1847. doi: 10.1016/0016–5085(93)90667–2

7. Maiden L., Th jodleifsson B., Th eodors A., Gonzalez J., Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology. 2005;128(5):1172–1178. doi: 10.1053/j.gastro.2005.03.020

8. Vane J. R. Inhibition of prostaglandin synthesis as a mecha nism of action for aspirin-like drugs. Nat New Biol. 1971;231(25):232–235. doi: 10.1038/newbio231232a0

9. Vane J. R., Bakhle Y. S., Botting R. M. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97–120. doi: 10.1146/annurev.pharmtox.38.1.97

10. Whittle B. J. Arachidonic acid metabolites and the gastro- intestinal toxicity of anti-infl ammatory agents. Prostaglandins. 1981;21 Suppl:113–118. Doi: 10.1016/0090–6980(81)90126-x

11. Peskar B. M. On the synthesis of prostaglandins by human gastric mucosa and its modification by drugs. Biochim Biophys Acta. 1977;487(2):307–314. doi: 10.1016/0005–2760(77)90007–8

12. Strub K. M., Muller R. K. Relation between ulcerogenic activity of various NSAID and their potency as inhibitors of prostaglandin synthesis in vivo. Agents Actions Suppl. 1979;(4):245–254. PMID: 115259

13. Whittle B. J. Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat. Gastroenterology. 1981;80(1):94–98. PMID: 6778761

14. Graham D. Y., Agrawal N. M., Roth S. H. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double- blind, placebo- controlled trial. Lancet. 1988;2(8623):1277–1280. doi: 10.1016/s0140–6736(88)92892–9

15. Jiranek G. C., Kimmey M. B., Saunders D. R., Willson R. A., Shanahan W., Silverstein F. E. Misoprostol reduces gastroduodenal injury from one week of aspirin: an endoscopic study. Gastroenterology. 1989;96(2 Pt 2 Suppl):656–661. Doi: 10.1016/s0016–5085(89)80062–9

16. Laine L., Takeuchi K., Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology. 2008;135(1):41–60. doi: 10.1053/j.gastro.2008.05.030

17. Rostom A., Muir K., Dube C., et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol. 2007;5(7):818–768. doi:10.1016/j.cgh.2007.03.011

18. Silverstein F. E., Graham D. Y., Senior J. R., et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-infl ammatory drugs. A randomized, double- blind, placebo- controlled trial. Ann Intern Med. 1995;123(4):241–249. doi: 10.7326/0003–4819–123–4–199508150–00001

19. Wallace J. L. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn’t the stomach digest itself?. Physiol Rev. 2008;88(4):1547–1565. doi: 10.1152/physrev.00004.2008

20. Wallace J. L., Caliendo G., Santagada V., Cirino G., Fiorucci S. Gastrointestinal safety and anti-infl ammatory eff ects of a hydrogen sulfi de- releasing diclofenac derivative in the rat. Gastroenterology. 2007;132(1):261–271. doi: 10.1053/j.gastro.2006.11.042

21. Syer S. D., Blackler R. W., Martin R., et al. NSAID enteropathy and bacteria: a complicated relationship. J Gastroenterol. 2015;50(4):387–393. doi: 10.1007/s00535–014–1032–1

22. Rollason V., Samer C. F., Daali Y., Desmeules J. A. Prediction by pharmacogenetics of safety and effi cacy of non-steroidal anti- infl ammatory drugs: a review. Curr Drug Metab. 2014;15(3):326–343. doi:10.2174/1389200215666140202214454